CD274 and cholangiocarcinoma: In recent times, immune checkpoint inhibitors, particularly those that block programmed death 1 and its ligand (PD1/PD-L1), have therefore emerged as promising strategies against a variety of cancers and are being increasingly integrated into the therapeutic landscape of CCA.